Paul Rabinowitz, MD
Allergy & Immunology · Atlanta, GANPI 1871564716
Payments from drug & device makers
Across 1,286 payments — averaging $72.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- Optinose US, Inc.$27K
- Boehringer Ingelheim$5K
- GSK$4K
- Genentech USA, Inc.$4K
- AstraZeneca$3K
- plus $12K from 32 others
What the payments were for
- Consulting fees$5,64710%
- Speaking & faculty fees$24,46043%
- Travel & lodging$2,9385%
- Food & beverage$23,85042%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 92 | $37,634 |
| Optinose US, Inc. | 116 | $26,819 |
| Boehringer Ingelheim | 37 | $5,315 |
| GSK | 259 | $4,264 |
| Genentech USA, Inc. | 14 | $4,127 |
| AstraZeneca | 103 | $3,135 |
| Sanofi | 105 | $2,266 |
| Sunovion Pharmaceuticals Inc. | 128 | $1,513 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,022 |
| Novartis | 42 | $989 |
| Grifols USA, LLC | 49 | $825 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $801 |
| CSL Behring | 31 | $789 |
| Pfizer | 44 | $737 |
| Amgen | 32 | $557 |
| Covis Pharma GmbH | 29 | $447 |
| Teva Pharmaceuticals USA, Inc. | 28 | $439 |
| Blueprint Medicines Corporation | 8 | $312 |
| ARS Pharmaceuticals Operations, Inc. | 18 | $280 |
| Circassia Inc. | 19 | $197 |
| Kaleo, Inc. | 9 | $163 |
| Organon | 10 | $153 |
| Genentech, Inc. | 1 | $150 |
| Biocryst US Sales Co., LLC | 6 | $125 |
| Mylan Specialty L.p. | 4 | $90 |
| Sumitomo Pharma America, Inc. | 11 | $84 |
| Alk-abello, Inc | 5 | $82 |
| Verona Pharma, Inc. | 2 | $67 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Merck | 2 | $37 |
| LEO Pharma Inc. | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Dermavant Sciences, Inc. | 1 | $21 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| GC Biopharma USA, Inc. | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,616 in reported general payments places this provider in the 85th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 200 | $167,845 |
| XolairOmalizumab | 28 | $92,018 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $46,214 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $37,989 |
| Spiriva RespimatTiotropium Bromide | 46 | $28,801 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 66 | $11,582 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $11,276 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,430 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $8,138 |
| Epinephrine | 26 | $4,876 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $4,438 |
| Azelastine Hcl | 102 | $3,935 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 158 | $3,597 |
| Montelukast Sodium | 239 | $2,562 |
| Ipratropium Bromide | 65 | $2,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $4,264 | $214,058297 claims |
| Genentech, Inc.Xolair | $150 | $92,01828 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,135 | $49,26592 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $5,315 | $39,23162 claims |
| Hikma Pharmaceuticals USAEpinephrine | $38 | $4,87626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Atlanta
- Deborah BirxAtlanta$470K
- Santhosh Kumar Bangalore Vasantha KumarAtlanta$60K
- Gerald LeeAtlanta$52K
- Luqman SeiduAtlanta$46K
- Alan ReddingAtlanta$23K
- David ReddingAtlanta$22K
- Merin KalangaraAtlanta$19K
- Glen NadelAtlanta$12K
- Keith LenchnerAtlanta$11K
- David TannerAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.